Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENFORCE national cohort study of COVID-19 vaccine effectiveness and safety
2020-006003-42Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran, elasomeran, ChAdOx1 nCoV-19 and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Rigshospitalet. Primary endpoint: Minimal protective neutralising antibody titre. Started Dec 2020; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-006003-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006003-42.